GEn1E has a pipeline of 2 preclinical stage products. The first is a P38 kinase inhibitor for the treatment of various inflammatory and aging diseases. The second is an endogenous non-antibiotic anti-bacterial agent for the treatment of Pseudomonas infections.
P38 Kinase Inhibitor Program
The P38 kinase inhibitor is being developed for a rare disease with no current FDA approved treatments, Acute Lung Injury (ALI)/Acute Respiratory Distress Syndrome (ARDS). Appx. 150,000 to < 200,000 patients have ALI/ARDS in the USA. Costs per patient are appx. $50,000 - $100,000 due to high ICU and ventilator costs, thus making it an area of huge unmet medical need. The lead compounds show strong in vitro and preclinical efficacy in an acute lung injury model.
The MUC1-ED is an endogenous non-antibiotic anti-bacterial agent for the treatment of Pseudomonas infections. 50% of all Cystic Fibrosis (CF) patients have Pseudomonas infections (appx. 15,000 patients in U.S.). Preclinical in vitro and in vivo animal data show good efficacy of MUC1-ED in Pseudomonas. Recombinant human MUC1-ED can be used along with antibiotics to reduce the bacterial load in infected patients while also slowing the development of antibiotic resistance by shortening the duration of infections.